Zydus Cadila gets USFDA for Decitabine Injection
Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Decitabine for Injection in the strength of 50 mg/vial Single-Dose Vial (USRLD: Dacogen).
Decitabine is used to treat myelodysplastic syndromes, certain types of blood or bone marrow cancer.
The drug will be manufactured at the group's injectables manufacturing facility at Zydus Hospira.
The group now has 326 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Cadila secures USFDA okay for Nelarabine Injection in US
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.
The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Read also: Zydus Pharma gets USFDA nod for Eluxadoline Tablets
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.